Pan-coronavirus fusion inhibitors as the hope for today and tomorrow

<正>The last two decades of the 21st century have seen emerging zoonotic coronavirus(Co V) diseases, including severe acute respiratory syndrome(SARS)(Holmes 2003),Middle East respiratory syndrome(MERS)(Graham et al.,2013) and coronavirus disease 2019(COVID-19)(Jiang et al., 2020), all posing a devastating threat to global public health and economy. Human common coronavirus 229E(HCo V-229E), HCo V-NL63 and HCo V-OC43 can cause upper respiratory infection in adults and children, even leading to fatal diseases(Morfopoulou et al., 2016; Konca et al., 2017; Veiga et al., 2020). Moreover, recent studies suggested that some bat-derived SARS-related coronaviruses(SARSr-Co Vs) have the potential to cause new Co V diseases in the future(Cui et al., 2019). This calls for the development of pan-Co V inhibitors to combat both current and future pandemics or epidemics of Co V diseases.